Please visit answersincme.com/WJM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses strategies for patient-centered management of immune-related adverse events (AEs) in patients receiving immunotherapy for nonmelanoma skin cancer (NMSC). Upon completion of this activity, participants should be better able to: Identify counseling strategies to educate patients and caregivers about AEs related to immunotherapy regimens for melanoma and NMSC; Describe monitoring schedules for short- and long-term immunotherapy-associated AEs; and Outline multidisciplinary management strategies for immunotherapy-associated AEs in dermatologic malignancies. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/ZPD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatologic diseases discusses the diagnosis and treatment of bullous pemphigoid. Upon completion of this activity, participants should be better able to: Review the clinical impact of bullous pemphigoid (BP) on patients; Outline diagnostic approaches to enhance the timely identification of patients with BP; and Identify clinical advances that may evolve the therapeutic paradigm for patients with BP.

Please visit answersincme.com/JZC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses the use of immunotherapy in advanced, unresectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Review current evidence-based recommendations informing the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; Describe the clinical profiles of immunotherapies for the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; and Outline potential considerations to optimize outcomes for patients with unresectable, locally advanced, recurrent, or metastatic CSCC who are on immunotherapies.

Please visit answersincme.com/UCA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the management of advanced basal cell carcinoma (BCC) with systemic therapy. Upon completion of this activity, participants should be better able to: Identify patients with BCC who are candidates for a systemic approach to treatment; Review the clinical implications of the evidence on approved and emerging systemic therapies in patients with advanced BCC; and Describe practical strategies to optimize systemic treatment over the long term for patients with advanced BCC. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/RKX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in skin cancer discusses strategies for adjuvant immunotherapy in resectable melanoma. Upon completion of this activity, participants should be better able to: Review the guideline-recommended role of adjuvant immunotherapy for the treatment of resectable melanoma; Describe the key adverse events associated with adjuvant immunotherapy for the treatment of resectable melanoma; Outline evidence-based, patient centric strategies to optimize the benefit-to-risk impact of adjuvant immunotherapy in resectable melanoma care

Please visit answersincme.com/GEU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the management of advanced basal cell carcinoma (BCC) with immunotherapies, based on the guidelines and clinical evidence. Upon completion of this activity, participants should be better able to: Review the guideline recommendations for the treatment of advanced BCC; Identify the clinical implications of the available evidence evaluating immunotherapy options for patients with advanced BCC; and Outline real-world considerations for the integration of immunotherapy into practice for the management of advanced BCC. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/GWE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in head and neck surgery discusses optimizing the in-practice use of neoadjuvant immunotherapy in the treatment of resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe clinical factors that should be considered when evaluating whether a patient with CSCC is a candidate for neoadjuvant immunotherapy; Review the clinical profiles of approved and emerging neoadjuvant immunotherapies for patients with resectable CSCC; and Outline practical considerations to optimize treatment outcomes for patients with resectable CSCC. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/UNV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology, immunology, and rheumatology discuss the management of psoriatic arthritis with novel targeted therapies. Upon completion of this activity, participants should be better able to: Recognize the rationale for novel TYK2 inhibitors in the treatment of psoriatic arthritis; Describe the latest clinical data informing the role of TYK2 inhibitors in the treatment of psoriatic arthritis; and Outline future management considerations for novel TYK2 inhibitors in the treatment of psoriatic arthritis.

Please visit answersincme.com/VWM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy discusses how to optimize the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbidities with biologic therapies. Upon completion of this activity, participants should be better able to: Identify patients with CRSwNP who are candidates for biologic therapies according to guideline recommendations; Describe best practices for monitoring response to biologic treatment of CRSwNP; and Outline treatment sequencing strategies to optimize the management of CRSwNP. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/JPC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses strategies to optimize the management of patients with moderate to severe hand and foot atopic dermatitis (AD), including treatment with novel systemic therapies. Upon completion of this activity, participants should be better able to: Describe the impacts of moderate to severe hand and foot AD on patients’ quality of life; Review the implications of the clinical data for novel systemic therapies in patients with moderate to severe hand and foot AD; and Outline practical, personalized approaches to optimize management of patients with moderate to severe hand and foot AD.